Abstract:
Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
Abstract:
An automatically operating interlock prevents connection of an electrical device within a cabinet unless the cabinet door is closed. The interlock is particularly useful for circuit breakers contained within arc-resistant cabinets. The interlock includes a spring-biased locking plate reciprocating between a locked position wherein the locking plate resists movement of the levering-in locking plate, and an unlocked position wherein the locking plate permits movement of the levering-in locking plate. The locking plate is spring-biased towards its locked position, and is pushed from its locked position to its unlocked position when the cabinet door is closed. Access to the hex drive of the levering-in rod is thereby resisted when the cabinet door is open.
Abstract:
The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations of antibodies and methods of making and using them.
Abstract:
The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations and methods of making and using them.
Abstract:
A modified bone morphogenetic protein (BMP, also referred to as bone morphogenic protein) composition is described. The bone morphogenetic protein, in one embodiment, is BMP-7 which is chemically modified with a hydrophilic polymer, such as poly(ethylene glycol).
Abstract:
A method for delivering a polypeptide to the central nervous system of a mammal is provided. The method involves attaching the polypeptide to an antibody or an antibody fragment and administering the fusion polypeptide intranasally, for delivery to the central nervous system. Methods of treatment are also provided, where a therapeutically effective amount of the composition is delivered to the nasal cavity of a mammal.
Abstract:
A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.
Abstract:
A switchgear cabinet includes a plurality of securing apparatuses that are mounted on a vertical flange of the switchgear cabinet, with the securing apparatuses each being formed with a locking hole that is engageable by a pin of a locking mechanism on a door member. Each securing apparatus includes an anchor plate connected with a first bracket and a second bracket, with the first and second brackets being mounted on the flange of the switchgear cabinet. The locking hole is formed in the anchor plate, and the anchor plate is substantially planar and free of bends. The anchor plate further is generally U-shaped and is configured to extend generally around at least a portion of the flange.
Abstract:
The present invention relates to non-aqueous high concentration reduced viscosity suspension formulations of antibodies and methods of making and using them.